Effectiveness of Hemophilia Medtep Platform in Prophylactic Treatment

Abstract

Introduction: Prophylactic treatment adherence is a critical factor in the control and evolution of patients with hemophilia, for the prevention of degenerative joint damage. The generalization of applications on mobile terminals, offers a therapeutic option in these patients, offering ample opportunities for therapeutic and preventive approach. The aim of this study is to assess the effectiveness of Haemophilia Medtep platform regarding adherence to prophylactic treatment.

Methods: Have been recruited 46 patients with hemophilia A and B in prophylaxis, over 13 years in different regions of Spain. Patients were invited to use the platform Hemophilia Medtep that can maintain a record of their treatment and bleeding processes which present. The effectiveness of the platform has been evaluated with the Spanish version of the VERITAS‐Pro scale, recently validated by our group, which evaluates the time of application, dosage, planning, memory, skip and communication. It has also been evaluated the perception of quality of life with the Short Form‐36 Health Survey (SF‐36). For statistical analysis we used the Student t test and Pearson correlation coefficient.

Results: The mean age of patients is 25.98 years (SD = 10.17), most with hemophilia A (86.7%) and severe phenotype (91.1%). 4% of the guest's patients were not registered to the platform and 11% did not activate your account. Table 1 data show participation. Of the total of patients registered and activated, 32 of them (82%) are still active after 6 months of use of therapeutic compliance platform with a reported 94%. After a month of use of the platform Hemophilia Medtep, significant differences in quality of life: Physical functioning (P < 0.05), Physical Function (P < 0.05), Vitality (P < 0.01) and physical component summary score (P < 0.01). There were also differences in adherence: Moment (P < 0.01), Planning (P < 0.05), Skip (P < 0.01) and Total (P < 0.01). Also there are correlations between completion and quality of life in general health (P = 0.299).

Discussion/Conclusion: The use of Medtep platform helps patients with hemophilia to improve adherence to prophylactic treatment. 70% of patients remain active recording their data in Hemophilia Medtep at 6 months of starting the study. These findings open new possibilities for therapeutic and preventive treatments of these patients, especially younger ones.